New leukemia treatment strategy aims for deep remission
NCT ID NCT05336812
Summary
This study is testing whether adding a second drug to acalabrutinib helps achieve deeper remission in people with previously untreated chronic lymphocytic leukemia (CLL). After one year on acalabrutinib alone, participants will be randomly assigned to receive either obinutuzumab or venetoclax alongside it for six months. The main goal is to see if these combinations can eliminate nearly all detectable cancer cells from the bone marrow.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.